adesso AG

12/17/2024 | Press release | Distributed by Public on 12/17/2024 03:47

Intelligent prevention: adesso ventures supports Noah Labs in relieving the burden on heart specialists

Press Releases

Dortmund| 17. December 2024

Intelligent prevention: adesso ventures supports Noah Labs in relieving the burden on heart specialists

The most common cause of hospitalisation in western industrialised nations? Cardiovascular diseases. The financial burden of cardiovascular patients on healthcare systems is enormous. Noah Labs co-founders Oliver Piepenstock, Marcus Hott, and Dr Leonhard Riehle are dedicated to alleviating the workload of cardiology practices and hospitals in Germany through AI-supported telemonitoring, while simultaneously enhancing the care provided to patients. The Noah Labs Ark software and the associated intelligent Connected Care platform enable comprehensive remote monitoring and management of chronic diseases based on classic vital parameters. The focus of the current application is on heart failure. However, high blood pressure and cardiac arrhythmia can also be monitored with the software. The solution received approval as a Class IIa medical device in accordance with the EU Medical Device Directive (MDR) in April 2024 and is already in use in numerous practices and clinics.

adesso ventures, the venture capital arm of IT service provider adesso, is supporting the Berlin-based start-up in its endeavours. In addition to a financial investment, Noah Labs will gain access to adesso's expertise and network in order to accelerate market penetration.

Early warning system for cardiovascular diseases

In today's standard cardiovascular screening, patients measure their vital parameters using medical devices such as scales, blood pressure monitors or ECGs. They send this data to their heart specialist at regular intervals for evaluation. The problem: the manual evaluation of vital data, in particular, causes significant delays in screening, making it challenging for cardiologists to respond promptly and potentially resulting in unnecessary and costly hospital admissions. The Noah Labs Ark platform connects certified medical devices such as smartwatches, ECGs, or blood pressure monitors, transmitting patient data in real time to medical practices or hospitals. The analytics engine developed by Noah Labs analyses the data according to specific biomarkers in order to assess the patient's state of health and make prognoses. For example, how should the increase in weight and body water be assessed in relation to blood pressure and heart rate? If a patient shows any abnormalities, the solution informs the relevant specialist so that measures can be taken at an early stage. This can be effective in reducing the number of hospital admissions.

An audible biomarker

Together with the German Heart Centre at the Charité hospital and the US Mayo Clinic, Noah Labs is currently conducting research into AI-supported voice-based diagnosis of heart disease. The approach: heart failure leads to water retention throughout the body, not least in the lungs, which can lead to pulmonary oedema in acute cases. Depending on the amount, these deposits affect the patient's voice. In extreme cases, this is already perceptible to the human ear. Artificial intelligence, however, could recognise nuances much earlier. The development and application of a non-invasive biomarker on this basis could significantly improve the accuracy of early diagnosis and monitoring of heart failure.

As part of three studies, the Analytics Engine from Noah Labs analyses voice samples from test subjects for hundreds of parameters in order to detect and evaluate even the smallest changes. The project partners will publish the initial study results shortly. The aim is to integrate the new biomarker and the AI model trained on it into Noah Labs Ark in the future, following successful testing.

The co-founders of Noah Labs from left to right: Dr. Leonhard Riehle, Marcus Hott and Oliver Piepenstock (Source: Noah Labs)

"With adesso, we have gained a supporter for our company that does more than just support us financially. The partnership-based collaboration with one of the largest IT service providers in Germany is particularly valuable for us," says Oliver Piepenstock, Co-Founder and CEO of Noah Labs. "Access to the concentrated AI and software expertise, the industry know-how and the extensive network in the healthcare sector will help us make decisive progress."

"The founders of Noah Labs are pursuing a vision that has the potential to revolutionise the prevention of cardiovascular disease," says Malte Unger, Managing Partner of adesso ventures. "With the mature and certified Ark platform, Noah Labs has an innovative solution on the market that is already relieving the burden on cardiologists and improving patient care enormously. And we are convinced that AI-supported voice-based diagnostics will drive the success of the platform even further in future."

Malte Unger is Managing Partner of adesso ventures. (Source: adesso)

"Digitalization in healthcare can not only optimize processes, but also significantly improve people's quality of life," adds Vanessa Schönen, Associate Business Development Manager in the business unit Health at adesso. "Noah Labs' approach shows that data-driven healthcare has great potential to relieve the load on healthcare service providers and payers. We will work together to leverage this potential."

Vanessa Schönen is Associate Business Development Manager of the Health business unit at adesso. (Source: adesso)

Press service

Materials for media reports

With our press service, we provide you with various materials that complement our corporate news or serve as background information.

To the press service

Do you have any questions?

Do you have any questions about our press service or a specific request? Please contact us.

PR-Manager Nils Roos +491704406148 [email protected]

Contact